MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biomark Diagnostics Inc (CSE:BUX)

0.5800 UNCHANGED
Streaming Delayed Price Updated: 9:30 AM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.5800
Bid (Size) 0.5700 (1,000)
Ask (Size) 0.6000 (5,500)
Prev. Close 0.5800
Today's Range 0.5800 - 0.5800
52wk Range 0.2600 - 0.6400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
Vancouver, British Columbia--(Newsfile Corp. - April 14, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"),... 
Via Newsfile
Topics Death
News headline image
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
Vancouver, British Columbia--(Newsfile Corp. - January 15, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a... 
Via Newsfile
Topics Artificial Intelligence

Performance

YTD
+27.5%
+27.5%
1 Month
N/A
N/A
3 Month
+9.4%
+9.4%
6 Month
+65.7%
+65.7%
1 Year
+114.8%
+114.8%

More News

Read More
News headline image
BioMark: 2025 Achievements & 2026 Vision
Via Newsfile
News headline image
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
Via Newsfile
Topics Artificial Intelligence
News headline image
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
Via Newsfile
News headline image
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Via Newsfile
Topics Artificial Intelligence
News headline image
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
Via Newsfile
Topics Artificial Intelligence
News headline image
BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
Via Newsfile
News headline image
BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy
Via Newsfile
Topics Intellectual Property
News headline image
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
Via Newsfile
News headline image
BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement
Via Newsfile
News headline image
BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay
Via Newsfile
Topics Intellectual Property
News headline image
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term
Via Newsfile
News headline image
BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives
Via Newsfile
Topics Artificial Intelligence
News headline image
BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test
Via Newsfile
News headline image
BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium
Via Newsfile
News headline image
BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team
Via Newsfile
Topics Intellectual Property
News headline image
Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay
Via Newsfile
Topics Intellectual Property
News headline image
BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting
Via Newsfile
News headline image
BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay
Via Newsfile
Topics Death Intellectual Property
News headline image
BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
Via Newsfile
News headline image
BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors
Via Newsfile
News headline image
Biomark Receives Funding Supporting Research and Development Project for Cancer Treatment Monitoring
Via Newsfile
News headline image
BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch
Via Newsfile
Topics Climate Change
News headline image
BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer
Via Newsfile
Topics Artificial Intelligence Death

Frequently Asked Questions

Is Biomark Diagnostics Inc publicly traded?
Yes, Biomark Diagnostics Inc is publicly traded.
What exchange does Biomark Diagnostics Inc trade on?
Biomark Diagnostics Inc trades on the Canadian Securities Exchange
What is the ticker symbol for Biomark Diagnostics Inc?
The ticker symbol for Biomark Diagnostics Inc is BUX on the Canadian Securities Exchange
What is the current price of Biomark Diagnostics Inc?
The current price of Biomark Diagnostics Inc is 0.5800
When was Biomark Diagnostics Inc last traded?
The last trade of Biomark Diagnostics Inc was at 05/14/26 09:30 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story